Cargando…
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954817/ https://www.ncbi.nlm.nih.gov/pubmed/33712562 http://dx.doi.org/10.1038/s41408-021-00438-y |
| _version_ | 1783664153997606912 |
|---|---|
| author | Richardson, Paul G. Facon, Thierry Bensinger, William I. Leleu, Xavier Campana, Frank Macé, Sandrine Chiron, Marielle van de Velde, Helgi Mikhael, Joseph |
| author_facet | Richardson, Paul G. Facon, Thierry Bensinger, William I. Leleu, Xavier Campana, Frank Macé, Sandrine Chiron, Marielle van de Velde, Helgi Mikhael, Joseph |
| author_sort | Richardson, Paul G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7954817 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79548172021-03-28 Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma Richardson, Paul G. Facon, Thierry Bensinger, William I. Leleu, Xavier Campana, Frank Macé, Sandrine Chiron, Marielle van de Velde, Helgi Mikhael, Joseph Blood Cancer J Correspondence Nature Publishing Group UK 2021-03-12 /pmc/articles/PMC7954817/ /pubmed/33712562 http://dx.doi.org/10.1038/s41408-021-00438-y Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Richardson, Paul G. Facon, Thierry Bensinger, William I. Leleu, Xavier Campana, Frank Macé, Sandrine Chiron, Marielle van de Velde, Helgi Mikhael, Joseph Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title | Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title_full | Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title_fullStr | Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title_full_unstemmed | Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title_short | Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| title_sort | predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954817/ https://www.ncbi.nlm.nih.gov/pubmed/33712562 http://dx.doi.org/10.1038/s41408-021-00438-y |
| work_keys_str_mv | AT richardsonpaulg predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT faconthierry predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT bensingerwilliami predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT leleuxavier predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT campanafrank predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT macesandrine predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT chironmarielle predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT vandeveldehelgi predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma AT mikhaeljoseph predictivebiomarkerswithisatuximabpluspomalidomideanddexamethasoneinrelapsedrefractorymultiplemyeloma |